Asma Azam

Asma Azam

Auto-generated profile, based on publicly available information

Asma Azam

Department of Medicine, Karachi Medical and Dental College Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Microbiologyopen
Verified
Journal Article
Open access
AAAsma Azam
Asma Azam
MQMuhammad Abdul Muqtadir Qureshi
Muhammad Abdul Muqtadir Qureshi
HZHafiz Shahbaz Zahoor
Hafiz Shahbaz Zahoor
SRSyeda Malaika Raza
Syeda Malaika Raza
MKMuhammad Mohsin Khan
Muhammad Mohsin Khan
AWAbdul Waheed
Abdul Waheed
Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.

18 December 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AAAsra Amjad
Asra Amjad
AAAsma Azam
Asma Azam
WSWadiha Shah
Wadiha Shah
UAUmair Ali
Umair Ali
MAMaryam Altaf
Maryam Altaf
MJMuhammad Rizwan Javed
Muhammad Rizwan Javed
Background: The gut-heart axis is a new therapeutic target for cardiovascular diseases, which continue to be the leading cause of death worldwide. Metabolites originating from microorganisms have demonstrated significant impacts on inflammation, remodeling, and heart function. Objective: By assessing molecular pathways, therapeutic options, and translational barriers, this narrative review seeks to objectively examine the cardioprotective potential of gut microbial metabolites. Methods: We reviewed and summarized the most recent research on the impact of microbial metabolites, both beneficial and detrimental, on endothelium repair, fibrosis, immunometabolism, and cardiac bioenergetics. A systematic search was conducted using the phrases “gut-heart axis,” “microbial metabolites,” and “cardiovascular protection” in PubMed, Scopus, and Web of Science for the years 2018–2024. Preclinical and clinical research that met the eligibility requirements were vetted and narratively synthesized. Results: By modulating Nrf2, HDAC, and TGF-β/Smad, protective metabolites such as short-chain fatty acids, urolithins, and indoles have anti-inflammatory, anti-fibrotic, and mitochondrial-enhancing properties. On the other hand, oxidative stress and fibrosis are made worse by trimethylamine N-oxide and hydrogen sulfide. Postbiotic formulations, innovative delivery systems, and synthetic biology provide promising approaches for focused intervention. However, there are substantial translational obstacles due to pharmacokinetic, regulatory, and microbiota heterogeneity. Conclusion: Microbial metabolites produced in the gut are a promising and revolutionary class of cardioprotectants. Future cardiovascular treatments may be redefined by precision-targeted gut-heart axis modulation, although clinical validation and regulatory standardization are still crucial.


1 January 2026 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
RPRumeesa Parveen
Rumeesa Parveen
MAM. Abdur Rahman Aizaz
M. Abdur Rahman Aizaz
SSSarah Sohail
Sarah Sohail
SJSara Jawaid
Sara Jawaid
AAAbdullah Amjad
Abdullah Amjad
SISakan Binte Imran
Sakan Binte Imran
Background: Diabetes mellitus (DM) is a metabolic disorder characterized by a consistently elevated blood sugar level. DM poses a major risk factor for many neurodegenerative diseases, causing a decline in cognitive function. BDNF (brain‐derived neurotrophic factor) is a neurotrophin in the central and peripheral nervous systems that plays a crucial role in the development of brain circuits. Hence, disturbance in levels of BDNF is linked to the occurrence of neurodegenerative diseases and cognitive decline in diabetic patients. Physical exercise has emerged as a nonpharmacological intervention in elevating BDNF levels. Our systematic review and meta‐analysis evaluate the relationship between a globally affecting metabolic disorder, diabetes, with decreased BDNF levels, and explore exercise as a promising potential intervention. Methods: After screening 37 articles, 4 studies have been included in the systematic review and meta‐analysis, out of which 3 of them are randomized controlled trials (RCTs), and 1 is a crossover trial. The search was conducted on PubMed (MEDLINE), ScienceDirect, Embase, Scopus, and Cochrane Central databases from inception to June 2025. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines were followed to conduct a systematic review. Cochrane risk‐of‐bias tool was used to assess the quality of the studies. Data were pooled using a random effect model. The protocol for this systematic review was registered in PROSPERO. Results: A total of 37 articles were screened, 3 RCTs and 1 crossover trial with 131 participants were included in the meta‐analysis. Serum BDNF levels were higher in the exercise group compared with controls (MD = 73.50; p = 0.05). A small reduction in body fat percentage in the exercise group compared with the control was found (MD = −1.24 % ; p = 0.17), which was not statistically significant. Body weight and fasting blood glucose (FBG) showed no statistically significant differences between the exercise and control groups (MD = 0.97; p = 0.65), (MD = −27.20; p = 0.31). Moderate to high heterogeneity was noticed across the data analyzed. Conclusion: This meta‐analysis overall concludes that regular exercise positively affects serum BDNF levels in diabetics. However, the small number of trials and small sample sizes has limited the conclusions. Further large‐scale RCTs are required to determine the long‐term neurological effects of exercise in diabetics.